EVRYSDI (Page 6 of 6)
PRINCIPAL DISPLAY PANEL — 60 mg/80 mL Bottle Carton
NDC 50242-175-07
Evrysdi®
(risdiplam)
for oral solution
60 mg/80 mL
(0.75 mg/mL)
Attention pharmacist: Evrysdi must beconstituted with water prior to dispensing.
80 mL (2.71 fl oz) total volume after constitution
Rx only
Genentech
10252477
| EVRYSDI risdiplam powder, for solution | ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| Labeler — Genentech Inc. (080129000) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| F. Hoffmann-La Roche AG | 482242971 | API MANUFACTURE (50242-175), ANALYSIS (50242-175), MANUFACTURE (50242-175), PACK (50242-175), LABEL (50242-175) | |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| F. Hoffmann-La Roche Ltd. | 485244961 | ANALYSIS (50242-175), LABEL (50242-175), PACK (50242-175), MANUFACTURE (50242-175) | |
Revised: 10/2023 Genentech Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.